Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 9713 - 9720 of 12086 results
Application Drafting Dangers Highlighted by Pacing Technologies v. Garmin International
March 6, 2015| Blog| Viewpoint
CMS Call Letter: Medicare Advantage Contracting Considerations
March 6, 2015| Blog| Viewpoint
And the Beat Goes On: NY State Assembly to Vote on GMO Labeling Law
March 5, 2015| Blog| Viewpoint
Some Thoughts on Employee Appreciation Day, including a Potential Wage and Hour Pitfall
March 5, 2015| Blog| Viewpoint
MLW: New Parental Leave Act Offers More Than Gender Neutrality
March 5, 2015| Blog| Viewpoint
Cleantech Law Alert: Jordan Collins on Open Atlantic Coast Oil and Gas Drilling, Restricted Alaskan Waters
March 5, 2015| Blog| Viewpoint
SEC Enforcement Director Discusses Issues for Pharmaceutical and Medical Technology Companies
March 5, 2015| Blog| Viewpoint
Floyd Advisory's Analysis of 2014 SEC Enforcement Actions
March 5, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|